コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ive PTB, 20 (6.3%) were culture-positive for Mycobacterium tuberculosis.
2 ions in the genomes of a pathogenic bacteria Mycobacterium tuberculosis.
3 sponse is a critical step in host control of Mycobacterium tuberculosis.
4 e, heat-killed Streptococcus pneumoniae, and Mycobacterium tuberculosis.
5 osome rescue process of trans-translation in Mycobacterium tuberculosis.
6 ands of primary human macrophages exposed to Mycobacterium tuberculosis.
7 PI) lansoprazole to be highly active against Mycobacterium tuberculosis.
8 d time required for genetic manipulations in Mycobacterium tuberculosis.
9 ycoside (AG) antibiotic kanamycin A (KAN) in Mycobacterium tuberculosis.
10 urther explored by screening 42 targets from Mycobacterium tuberculosis.
11 ficant human disease caused by inhalation of Mycobacterium tuberculosis.
12 ment against antibiotic resistant strains of Mycobacterium tuberculosis.
13 n primates (NHP) infected with a low dose of Mycobacterium tuberculosis.
14 ated the relevance of LILR in the context of Mycobacterium tuberculosis.
15 al cytokine in the innate immune response to Mycobacterium tuberculosis.
16 that specifically target this population of Mycobacterium tuberculosis.
17 emergence of multidrug-resistant strains of Mycobacterium tuberculosis.
18 mycolic acids, required for the cell wall of Mycobacterium tuberculosis.
19 monocytogenes (rLm) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protei
20 as a pharmacophore to generate inhibitors of Mycobacterium tuberculosis acetyltransferase Eis, whose
21 med to model the incidence of infection with Mycobacterium tuberculosis among adults using data on in
23 sential role in the early immune response to Mycobacterium tuberculosis and are the cell type prefere
24 ased approach on malate synthase (GlcB) from Mycobacterium tuberculosis and discovered several novel
25 cells from healthy donors were cultured with Mycobacterium tuberculosis and extracellular matrix in a
28 etween topoisomerase I and RNA polymerase in Mycobacterium tuberculosis and Mycobacterium smegmatis t
29 es that infect mycobacterial hosts including Mycobacterium tuberculosis and Mycobacterium smegmatis,
30 ights on the efficacy of human antibodies to Mycobacterium tuberculosis and on how functional heterog
32 sive and sensitive WGS assay to characterize Mycobacterium tuberculosis and other M. tuberculosis com
35 ls) whole-genome shotgun (WGS) sequencing of Mycobacterium tuberculosis and soil micro-colonies with
36 n the virulence of human pathogens including Mycobacterium tuberculosis and Staphylococcus aureus.
37 MTB/RIF have advanced our ability to detect Mycobacterium tuberculosis and to determine antimicrobia
38 riminately promote intracellular infections (Mycobacterium tuberculosis), and had no effect on extrac
39 isseria meningitidis, Mycoplasma pneumoniae, Mycobacterium tuberculosis, and Bartonella), and 13 viru
41 tor PhoP is an essential virulence factor in Mycobacterium tuberculosis, and it presents a target for
42 C from Bacillus anthracis, Escherichia coli, Mycobacterium tuberculosis, and Vibrio cholerae is a dim
46 se compounds inhibit intracellular growth of Mycobacterium tuberculosis, are nontoxic to human cell l
47 richia coli and the tripartite TAC system of Mycobacterium tuberculosis as a model to investigate how
49 d guinea pig model of aerosol infection with Mycobacterium tuberculosis, BCG and MTBVAC delivered via
52 tor regulatory network of the human pathogen Mycobacterium tuberculosis by an integrated approach.
53 us, augmenting host immune responses against Mycobacterium tuberculosis by harnessing the SET8-NQO1/T
60 e Calmette-Guerin (BCG) as a surrogate for a Mycobacterium tuberculosis challenge, would facilitate v
62 ow and cumbersome laboratory diagnostics for Mycobacterium tuberculosis complex (MTBC) risk delayed t
63 n of six species of mycobacteria, i.e., both Mycobacterium tuberculosis complex (MTC) and nontubercul
68 ed the performance of amplicon sequencing of Mycobacterium tuberculosis DNA from patient sputum sampl
69 rasound-guided aspiration, PCR and Amplified Mycobacterium tuberculosis DNA test confirmed tubercular
71 The emergence and spread of drug-resistant Mycobacterium tuberculosis (DR-TB) are critical global h
73 r previously described mathematical model of Mycobacterium tuberculosis dynamics in Western Province,
75 ry protein, an enoyl reductase enzyme in the Mycobacterium tuberculosis fatty acid biosynthesis pathw
79 These technologies detect mutations in the Mycobacterium tuberculosis genome that confer phenotypic
80 d recombineering to identify the target of a Mycobacterium tuberculosis growth inhibitor, pointed to
81 is protection is due to direct inhibition of Mycobacterium tuberculosis growth, which prevents subseq
82 st that among the reasons for attenuation of Mycobacterium tuberculosis H37Ra is a mutation in the ph
83 (CyC) analogs have been investigated against Mycobacterium tuberculosis H37Rv (M. tb) grown either in
87 experimental evidence supports the idea that Mycobacterium tuberculosis has evolved strategies to sur
89 toxin gene pairs, and some pathogens such as Mycobacterium tuberculosis have over 90 toxin-antitoxin
90 he virulence and persistence of M. bovis and Mycobacterium tuberculosis Here, we describe a novel fun
91 xoplasma gondii, Listeria monocytogenes, and Mycobacterium tuberculosis However, relatively little is
92 ssential for control of pathogens, including Mycobacterium tuberculosis However, the mechanisms by wh
93 has been identified as a drugable target in Mycobacterium tuberculosis, however previously identifie
95 scherichia coli, Salmonella typhimurium, and Mycobacterium tuberculosis in human and mouse macrophage
96 stigated lactational transfer of immunity to Mycobacterium tuberculosis in MHC class I-mismatched ani
97 iochemical methods to study the dUTPase from Mycobacterium tuberculosis In particular, the RAMD appro
98 imes for conventional methods used to detect Mycobacterium tuberculosis in sputum samples and to obta
100 n immunodominant and diagnostic antigen from Mycobacterium tuberculosis, in Salmonella enterica serov
101 occus pneumoniae, Legionella pneumophila, or Mycobacterium tuberculosis-in a case study to show how o
102 d in vitro and intracellular potency against Mycobacterium tuberculosis, including multidrug-resistan
103 CXCL1 and CXCL2 can significantly reduce the Mycobacterium tuberculosis-induced bioactive IL-1beta pr
105 ine-proline-glutamic acid (PPE)17 protein of Mycobacterium tuberculosis induces TLR1/2 heterodimeriza
106 recognized by CD4-positive T lymphocytes of Mycobacterium tuberculosis-infected humans has recently
108 abundantly expressed in pulmonary lesions in Mycobacterium tuberculosis-infected nonhuman primates du
109 onducted a prospective cohort study with 834 Mycobacterium tuberculosis-infected patients from select
110 atest risk factor for reactivation of latent Mycobacterium tuberculosis infection (LTBI) and progress
111 cently acquired and remotely acquired latent Mycobacterium tuberculosis infection (LTBI) are clinical
112 ventions that shrink the reservoir of latent Mycobacterium tuberculosis infection (preventive therapy
113 he epitopes identified in people with latent Mycobacterium tuberculosis infection and treated patient
114 vaccine that induces sterilizing immunity to Mycobacterium tuberculosis infection has been elusive.
115 ranscriptional changes immediately following Mycobacterium tuberculosis infection have not been evalu
117 ich type I IFN may confer protection against Mycobacterium tuberculosis infection in the absence of I
120 e of antibodies (Abs) in the defense against Mycobacterium tuberculosis infection remains uncertain.
121 thylase (H4K20me1), is highly induced during Mycobacterium tuberculosis infection that orchestrates i
122 ssay results for predicting progression from Mycobacterium tuberculosis infection to active disease i
123 rs that prospectively predict progression of Mycobacterium tuberculosis infection to tuberculosis dis
126 e determined the role of IL-21R signaling in Mycobacterium tuberculosis infection, using IL-21R knock
127 platform and an in vitro macrophage model of Mycobacterium tuberculosis infection, we identified seve
128 necrosis factor (TNF) is crucial to control Mycobacterium tuberculosis infection, which remains a le
134 crucial for host resistance against chronic Mycobacterium tuberculosis infection; however, which cel
135 lity in the timing of clinical disease after Mycobacterium tuberculosis infection; incident disease c
136 synthase, is effective for the treatment of Mycobacterium tuberculosis infections that no longer res
138 so apply our method to large-scale data from Mycobacterium tuberculosis involving ChIP-seq data on 11
139 g of the genetic basis of drug resistance in Mycobacterium tuberculosis is critical for prompt diagno
147 MDR-TB), caused by drug-resistant strains of Mycobacterium tuberculosis, is an increasingly serious p
148 ties and that M. smegmatis, in contrast with Mycobacterium tuberculosis, is not able to use alternati
149 el method, PyroTyping, for discrimination of Mycobacterium tuberculosis isolates combining pyrosequen
151 ci, 5 Gram-negative nonfermenting species, 9 Mycobacterium tuberculosis isolates, and 5 miscellaneous
152 Tn-Seq libraries made in isogenic strains of Mycobacterium tuberculosis lacking three different genes
153 a delay in innate immune response to inhaled Mycobacterium tuberculosis, leading to delayed adaptive
154 elated well, showing for the first time that Mycobacterium tuberculosis, likely to be phenotypically
158 lion individuals were latently infected with Mycobacterium tuberculosis (M.tb) globally in 2014, just
159 Humans serve as both host and reservoir for Mycobacterium tuberculosis, making tuberculosis a theore
160 ake in all representative bacteria including Mycobacterium tuberculosis; mannitol, with selective upt
161 an be used to study host immune responses to Mycobacterium tuberculosis Mauritian cynomolgus macaques
164 sis infection limited the growth of virulent Mycobacterium tuberculosis more efficiently than those i
166 trans-phosphorylating phosphodiesterase from Mycobacterium tuberculosis (mPDE), that resulted in decr
168 second step in the biosynthesis of biotin in Mycobacterium tuberculosis (Mtb) and is an essential enz
171 ogens such as Staphylococcus aureus (SA) and Mycobacterium tuberculosis (Mtb) are appreciably sensiti
175 ll greater than 99% of exponentially growing Mycobacterium tuberculosis (Mtb) cells, but the remainin
178 the structure and interactions of avidin and Mycobacterium tuberculosis (Mtb) CYP142A1 were assessed
180 ty, they must detect </=10 genomic copies of Mycobacterium tuberculosis (MTB) DNA, the limit of detec
182 e antibiotic with selective activity against Mycobacterium tuberculosis (Mtb) due to mechanism-based
183 e glyoxylate shunt, an essential pathway for Mycobacterium tuberculosis (Mtb) during the persistent p
188 The library was evaluated for inhibition of Mycobacterium tuberculosis (Mtb) growth and Mtb Antigen
193 Drug discovery efforts against the pathogen Mycobacterium tuberculosis (Mtb) have been advanced thro
195 imately 35000 compounds was screened against Mycobacterium tuberculosis (Mtb) in order to identify no
196 ealthcare workers (HCWs) are at high risk of Mycobacterium tuberculosis (Mtb) infection and tuberculo
197 RATIONALE: How host genetic factors affect Mycobacterium tuberculosis (Mtb) infection outcomes rema
199 se antigens expressed at different stages of Mycobacterium tuberculosis (Mtb) infection, in particula
200 ositive QuantiFERON-TB test is indicative of Mycobacterium tuberculosis (Mtb) infection, which predis
201 tum-based quantitative test to detect active Mycobacterium tuberculosis (Mtb) infections in clinicall
203 Recent data indicate that the metabolism of Mycobacterium tuberculosis (Mtb) inside its host cell is
204 creted antigenic target of 6 kDa (ESAT-6) of Mycobacterium tuberculosis (Mtb) is an essential virulen
205 inated and lymph node tuberculosis, in which Mycobacterium tuberculosis (Mtb) is predominantly intrac
208 In total, 303 randomly selected clinical Mycobacterium tuberculosis (MTB) isolates from 303 patie
214 al, structural and metabolomic evidence that Mycobacterium tuberculosis (Mtb) PYK uses AMP and glucos
215 rst line anti-TB drugs against intracellular Mycobacterium tuberculosis (Mtb) residing inside macroph
218 nscriptional repressor of EthA expression in Mycobacterium tuberculosis (Mtb) that reduces the effica
221 DNA polymerase DnaE1 from the major pathogen Mycobacterium tuberculosis (Mtb) uses its intrinsic PHP-
222 respiratory syndrome coronavirus (MERS-CoV), Mycobacterium tuberculosis (MTB), and human papillomavir
223 Lipomannan (LM), found on the surface of Mycobacterium tuberculosis (Mtb), is actively involved i
227 are critical for protective immunity against Mycobacterium tuberculosis (Mtb), the cause of tuberculo
229 he host protein composition of exosomes from Mycobacterium tuberculosis (Mtb)-infected cells have not
237 Epistem Genedrive assay rapidly detects the Mycobacterium tuberculosis omplex from sputum and is cur
238 h-resolution crystal structures of LipA from Mycobacterium tuberculosis: one in its resting state and
239 e are 11 serine/threonine protein kinases in Mycobacterium tuberculosis, only one serine/threonine ph
240 vation of the unusual beta-lactam targets of Mycobacterium tuberculosis or for escaping to hydrolysis
241 t bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or related mycobacterial spe
242 t would enhance the killing of intracerebral Mycobacterium tuberculosis organisms and decrease the ra
243 gly, TrmD proteins from Escherichia coli and Mycobacterium tuberculosis, organisms known to synthesiz
244 ersity and resistance determinants of Indian Mycobacterium tuberculosis, particularly for the primary
245 ances that have facilitated investigation of Mycobacterium tuberculosis pathogenesis, analysis of ess
247 tudy, we report that CD1c tetramers carrying Mycobacterium tuberculosis phosphomycoketide bind gammad
249 Mycobacteria, including the human pathogen Mycobacterium tuberculosis, produce a complex cell wall
250 e, rhIFN-gamma reversed defective control of Mycobacterium tuberculosis proliferation by patients' ma
251 mer) reagents with subnanomolar affinity for Mycobacterium tuberculosis proteins (antigens 85A, 85B,
252 mechanisms governing neutrophil response to Mycobacterium tuberculosis remain poorly understood.
257 ine protein kinase, is a virulence factor in Mycobacterium tuberculosis, required for inhibition of p
258 berculosis, caused by the bacterial pathogen Mycobacterium tuberculosis, requires months of antibioti
261 hylococcus aureus, Streptococcus pneumoniae, Mycobacterium tuberculosis, Salmonella enterica, Klebsie
262 have differentiated Mycobacterium bovis from Mycobacterium tuberculosis since 2005, we review the epi
263 understanding of HIV-induced alterations of Mycobacterium tuberculosis-specific CD4(+) T cells that
265 hesion to type I collagen and fibronectin by Mycobacterium tuberculosis-stimulated monocytes increase
268 alphabeta) contribute to the pathogenesis of Mycobacterium tuberculosis strains that induce high IFN-
269 (MDR), and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains, has superior ADMET p
273 ystem capable of bacterial identification of Mycobacterium tuberculosis (TB) and Acinetobacter bauman
277 elops in only 5%-10% of humans infected with Mycobacterium tuberculosis The mechanisms underlying thi
279 (F-ATP) synthase is essential for growth of Mycobacterium tuberculosis, the causative agent of tuber
282 n, 6kDa) is a major virulence determinant of Mycobacterium tuberculosis, the cause of human tuberculo
284 s exhibit potent and selective inhibition of Mycobacterium tuberculosis, the etiological agent of TB,
285 sed incidence of tuberculosis (TB) caused by Mycobacterium tuberculosis there is an urgent need for n
286 Given the active site similarities between Mycobacterium tuberculosis ThyX (Mtb-ThyX) and Tm-ThyX,
287 disease that has developed sufficiently for Mycobacterium tuberculosis to be present in the airways.
288 ved to be among the major mechanisms used by Mycobacterium tuberculosis to escape protective host imm
289 identified the repertoire of RNAs cleaved by Mycobacterium tuberculosis toxin MazF-mt9 using an RNA-s
291 a prototypic host-adapted airborne pathogen, Mycobacterium tuberculosis traverses the lung and has se
292 lecules targeting the cytochrome bc1 :aa3 in Mycobacterium tuberculosis triggered interest in the ter
294 nd specific identification of drug-resistant Mycobacterium tuberculosis using RPA under specific cond
298 , as well as Corynebacterium diphtheriae and Mycobacterium tuberculosis, which cause devastating huma
299 lations of metabolically active and inactive Mycobacterium tuberculosis with unknown implications for
300 stion by studying the population dynamics of Mycobacterium tuberculosis within tuberculosis patients
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。